← Back to patent-cliff list
SXR-1096
Tier C — Watch / tradeSXR-1096
Sixera Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KLK5, KLK7, KLK14
Indications (approved)：Netherton综合征
Regional status
US
-
EU
Phase II
2021-08-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SXR-1096?
Approved indications include: Netherton综合征.
When does the SXR-1096 patent expire?
No public expiry year is available for SXR-1096 yet; this page updates once verified.
How do I get a quote for SXR-1096 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06